{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:05:32Z","timestamp":1792105532409,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["3253"],"award-info":[{"award-number":["3253"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["312768"],"award-info":[{"award-number":["312768"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["324151"],"award-info":[{"award-number":["324151"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020986","name":"Fondation de l'H\u00f4pital g\u00e9n\u00e9ral juif","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013455","name":"Lady Davis Institute for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013455","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004734","name":"Jewish General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013020","name":"Compute Canada","doi-asserted-by":"publisher","award":["RRG #4318"],"award-info":[{"award-number":["RRG #4318"]}],"id":[{"id":"10.13039\/100013020","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40257-023-00763-x","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:02:56Z","timestamp":1676530976000},"page":"359-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009\u20132022)"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9773-3515","authenticated-orcid":false,"given":"Alex","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4674-5695","authenticated-orcid":false,"given":"Pingxing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-4675","authenticated-orcid":false,"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-7956","authenticated-orcid":false,"given":"Philippe","family":"Lefran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"issue":"10","key":"763_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015;151(10):1081\u20136.","journal-title":"JAMA Dermatol"},{"issue":"9715","key":"763_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","volume":"375","author":"V Madan","year":"2010","unstructured":"Madan V, Lear JT, Szeimies R-M. Non-melanoma skin cancer. The Lancet. 2010;375(9715):673\u201385.","journal-title":"The Lancet"},{"issue":"4","key":"763_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ejca.2013.12.013","volume":"50","author":"M McCusker","year":"2014","unstructured":"McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf D, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014;50(4):774\u201383.","journal-title":"Eur J Cancer"},{"issue":"23","key":"763_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"763_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41416-020-01220-w","volume":"124","author":"BJ Verkouteren","year":"2021","unstructured":"Verkouteren BJ, Wakkee M, Reyners AK, Nelemans P, Aarts MJ, R\u00e1cz E, et al. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. Br J Cancer. 2021;124(7):1199\u2013206.","journal-title":"Br J Cancer"},{"issue":"5","key":"763_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2016.06.020","volume":"75","author":"G Goldenberg","year":"2016","unstructured":"Goldenberg G, Karagiannis T, Palmer JB, Lotya J, O\u2019Neill C, Kisa R, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. J Am Acad Dermatol. 2016;75(5):957-66.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"763_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJM196005052621803","volume":"262","author":"RJ Gorlin","year":"1960","unstructured":"Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262(18):908\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"763_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrc2503","volume":"8","author":"EH Epstein","year":"2008","unstructured":"Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"763_CR9","doi-asserted-by":"publisher","first-page":"12125","DOI":"10.1074\/jbc.271.21.12125","volume":"271","author":"H Hahn","year":"1996","unstructured":"Hahn H, Christiansen J, Wicking C, Zaphiropoulos PG, Chidambaram A, Gerrard B, et al. A Mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. J Biol Chem. 1996;271(21):12125\u20138.","journal-title":"J Biol Chem"},{"issue":"1","key":"763_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ng0996-78","volume":"14","author":"MR Gailani","year":"1996","unstructured":"Gailani MR, St\u00e5hle-B\u00e4ckdahl M, Leffell DJ, Glyn M, Zaphiropoulos PG, Und\u00e9n AB, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14(1):78\u201381.","journal-title":"Nat Genet"},{"issue":"5678","key":"763_CR11","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1126\/science.1098020","volume":"304","author":"L Lum","year":"2004","unstructured":"Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science. 2004;304(5678):1755\u20139.","journal-title":"Science"},{"issue":"7","key":"763_CR12","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1001\/jamadermatol.2016.0780","volume":"152","author":"AA Jacobsen","year":"2016","unstructured":"Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816\u201324.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"763_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.","journal-title":"BMC Cancer"},{"issue":"6","key":"763_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","volume":"72","author":"A Sekulic","year":"2015","unstructured":"Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-6.e8.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"763_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716\u201328.","journal-title":"Lancet Oncol"},{"issue":"6","key":"763_CR16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369\u201378.","journal-title":"Br J Dermatol"},{"issue":"5","key":"763_CR17","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-14-1234","volume":"21","author":"J Goldman","year":"2015","unstructured":"Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, et al. Phase I dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015;21(5):1002\u20139.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"763_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","volume":"32","author":"DJ Kim","year":"2014","unstructured":"Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745\u201351.","journal-title":"J Clin Oncol"},{"issue":"6","key":"763_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jaad.2018.07.004","volume":"79","author":"P Xie","year":"2018","unstructured":"Xie P, Lefrancois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(6):1089-100 e17.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"763_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Internal Med. 2009;151(4):264\u20139.","journal-title":"Ann Internal Med."},{"issue":"9","key":"763_CR21","first-page":"956","volume":"14","author":"KS Viscusi","year":"2015","unstructured":"Viscusi KS, Hanke CW. Vismodegib for locally advanced basal cell carcinoma: descriptive analysis of a case series and comparison to the literature. J Drugs Dermatol. 2015;14(9):956\u201362.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"763_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jaad.2015.07.016","volume":"73","author":"G Tauber","year":"2015","unstructured":"Tauber G, Pavlovsky L, Fenig E, Hodak E. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. J Am Acad Dermatol. 2015;73(5):799\u2013801.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"763_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","volume":"160","author":"OK Ozgur","year":"2015","unstructured":"Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220-7.e2.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"763_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaad.2015.03.013","volume":"73","author":"H Sofen","year":"2015","unstructured":"Sofen H, Gross KG, Goldberg LH, Sharata H, Hamilton TK, Egbert B, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73(1):99-105.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"763_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","volume":"31","author":"H Demirci","year":"2015","unstructured":"Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of Vismodegib (Erivedge\u2122) for basal cell carcinoma involving the orbit and periocular area. Ophthalmic Plast Reconstr Surg. 2015;31(6):463.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"763_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","volume":"70","author":"ALS Chang","year":"2014","unstructured":"Chang ALS, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day B-M, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"763_CR27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","volume":"131","author":"HS Gill","year":"2013","unstructured":"Gill HS, Moscato EE, Chang ALS, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(12):1591\u20134.","journal-title":"JAMA Ophthalmol."},{"issue":"12","key":"763_CR28","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"DD Von Hoff","year":"2009","unstructured":"Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164\u201372.","journal-title":"N Engl J Med"},{"issue":"6","key":"763_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaad.2015.12.035","volume":"74","author":"PD Simone","year":"2016","unstructured":"Simone PD, Schwarz JM, Strasswimmer JM. Four-year experience with vismodegib hedgehog inhibitor therapy. J Am Acad Dermatol. 2016;74(6):1264\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-Seguin","year":"2017","unstructured":"Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348.","journal-title":"Eur J Cancer"},{"key":"763_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100844","volume":"35","author":"N Bertrand","year":"2021","unstructured":"Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. EClinicalMedicine. 2021;35: 100844.","journal-title":"EClinicalMedicine."},{"issue":"7","key":"763_CR32","doi-asserted-by":"publisher","first-page":"e1240","DOI":"10.1002\/onco.13820","volume":"26","author":"A Kahana","year":"2021","unstructured":"Kahana A, Unsworth SP, Andrews CA, Chan MP, Bresler SC, Bichakjian CK, et al. Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: the VISORB trial. Oncologist. 2021;26(7):e1240\u20139.","journal-title":"Oncologist"},{"key":"763_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.563404","volume":"10","author":"MC Tronconi","year":"2020","unstructured":"Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A. Tailored toxicity-driven administration of Vismodegib in patients with multiple or locally advanced basal cell carcinoma: a pilot analysis. Front Oncol. 2020;10: 563404.","journal-title":"Front Oncol"},{"issue":"3","key":"763_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s13555-019-0303-4","volume":"9","author":"A Villani","year":"2019","unstructured":"Villani A, Fabbrocini G, Cappello M, Costa C, Scalvenzi M. Real-Life Effectiveness of Vismodegib in patients with metastatic and advanced basal cell carcinoma: characterization of adverse events and assessment of health-related quality of life using the dermatology life quality index (DLQI) test. Dermatol Ther (Heidelb). 2019;9(3):505\u201310.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"6","key":"763_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.abd.2021.04.012","volume":"96","author":"C Xavier","year":"2021","unstructured":"Xavier C, Lopes E, Bexiga C, Moura C, Gouveia E, Duarte AF. Vismodegib for treatment of periocular basal cell carcinoma\u20146-year experience from a tertiary cancer center. An Bras Dermatol. 2021;96(6):712\u20136.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"763_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262151","volume":"17","author":"A Sekulic","year":"2022","unstructured":"Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang ALS, et al. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS ONE. 2022;17(1): e0262151.","journal-title":"PLoS ONE"},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/CCID.S233097","volume":"13","author":"JT Lear","year":"2020","unstructured":"Lear JT, Hauschild A, Stockfleth E, Squittieri N, Basset-Seguin N, Dummer R. Efficacy and safety of sonidegib in adult patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome): results from a phase 2, double-blind, randomized trial. Clin Cosmet Investig Dermatol. 2020;13:117\u201321.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"23","key":"763_CR38","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","volume":"366","author":"JY Tang","year":"2012","unstructured":"Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"763_CR39","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404\u201312.","journal-title":"Lancet Oncol"},{"issue":"12","key":"763_CR40","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","volume":"26","author":"V Belum","year":"2015","unstructured":"Belum V, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol. 2015;26(12):2496\u2013502.","journal-title":"Ann Oncol"},{"issue":"6","key":"763_CR41","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1111\/bjd.13630","volume":"172","author":"S Alkeraye","year":"2015","unstructured":"Alkeraye S, Maire C, Desmedt E, Templier C, Mortier L. Persistent alopecia induced by vismodegib. Br J Dermatol. 2015;172(6):1671\u20132.","journal-title":"Br J Dermatol"},{"issue":"4","key":"763_CR42","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00520-015-2932-1","volume":"24","author":"M Le Moigne","year":"2016","unstructured":"Le Moigne M, Saint-Jean M, Jirka A, Qu\u00e9reux G, Peuvrel L, Brocard A, et al. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer. 2016;24(4):1689\u201395.","journal-title":"Support Care Cancer"},{"issue":"12","key":"763_CR43","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1194\/jlr.R025882","volume":"53","author":"RAK Srivastava","year":"2012","unstructured":"Srivastava RAK, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid Res. 2012;53(12):2490\u2013514.","journal-title":"J Lipid Res"},{"issue":"1","key":"763_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08968-1","volume":"21","author":"R Gutzmer","year":"2021","unstructured":"Gutzmer R, Robert C, Loquai C, Schadendorf D, Squittieri N, Arntz R, et al. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer. 2021;21(1):1\u20139.","journal-title":"BMC Cancer"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00763-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00763-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T01:14:59Z","timestamp":1684372499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00763-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00763-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"7 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by research grants from the Lady Davis Institute for Medical Research, the Jewish General Hospital Foundation, the Jewish General Hospital Department of Medicine, the Fonds de recherche du Qu\u00e9bec\u2014Sant\u00e9 (#312768 and #324151), and the Marathon of Hope Cancer Centre Network\u2014Terry Fox Research Institute (#3253). This research was enabled in part by support provided by Calcul Qu\u00e9bec (\n                      \n                      ), Compute Ontario (\n                      \n                      ), WestGrid (\n                      \n                      ), and the Digital Research Alliance of Canada (\n                      \n                      ) (RRG #4318).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alex Nguyen, Pingxing Xie, Ivan V. Litvinov, and Philippe Lefran\u00e7ois declare they have no conflicts of interest that may be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interest"}},{"value":"The contents of this manuscript have not been previously published entirely or in part, is not under consideration by another journal, and has not been simultaneously submitted elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: PL. Methodology: PX and PL. Formal analysis: AN, PX, and PL. Investigation: AN. Resources: PL. Data curation: AN, PX, and PL. Writing\u2014original draft preparation: AN. Writing\u2014reviewing and editing: AN, PX, IVL, and PL. Supervision: IVL and PL. Funding acquisition: PL. All authors have read and agreed to the published version of this manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}